Synergistic effects of laser interstitial thermal therapy (LITT) and immunotherapy for brain tumor recurrence: A systematic review and meta-analysis - 10/01/25
, Oguz Kagan Sahin b, Paweł Łajczak c, Numa Rajab d, Aisha Rizwan Ahmed e, Yasmin Picanço Silva f, Ayesha Bakhsh g, Anoushka Chatterjee f, Mohammed Raake h, Walter Fagundes iHighlights |
• | LITT and immunotherapy show promise as a synergistic approach for recurrent brain tumors. |
• | Combined therapy resulted in a median survival of 12.8 months for treated patients. |
• | Only 6% of patients experienced adverse events, demonstrating a favorable safety profile. |
• | LITT may enhance immunotherapy efficacy by boosting the immune response against tumors. |
Abstract |
Purpose |
The confluence of laser interstitial thermal therapy (LITT) with immunotherapeutic approaches represents a promising option for managing recurrent brain lesions. However, the potential synergy between these modalities is still unclear. This meta-analysis examines the literature to elucidate the adverse effects and overall survival associated with this combination in treating recurrent brain metastases and glioblastoma.
Methods |
Systematic searches were performed on PubMed, Embase, and Web of Science databases. Inclusion criteria comprised studies investigating the combined utilization of LITT with immunotherapy, among adult patients diagnosed with recurrent brain metastases and recurrent glioblastoma. Our analysis, using a random-effects model, pooled Overall Survival (OS) and Adverse events (AEs) from all the included studies.
Results |
We analyzed 162 patients from one RCT and three non-randomized studies. The pooled analysis of all patients revealed a median OS of 12.8 months (95% CI = 8.31–17.31; p < 0.01) with the combined treatment of LITT and immunotherapy. Similarly, approximately 6% of patients experienced AEs (95% CI = −0.01–0.11; p = 0.03). Subgroup analysis further demonstrated that among patients with recurrent glioma, the combined treatment showed pooled OS of 11 months (95% CI = 7.13–16.62; p < 0.01), while AEs were observed in 4% of patients (95% CI = −0.02–0.10; p = 0.21).
Conclusion |
This meta-analysis showed a potentially comparable safety profile and overall survival to conventional treatment modalities. Further research is warranted to test differences in the incidence of AEs and OS from LITT with immunotherapy versus a control.
Le texte complet de cet article est disponible en PDF.Abbreviations : AE, CAR T-cell, GBM, LITT, LITT + IT, LOE, NOS, OR, PRISMA, RCT
Keywords : Laser interstitial thermal therapy (LITT), Immunotherapy, Synergy, Recurrent brain cancer, Meta-analysis
Plan
Vol 71 - N° 2
Article 101629- mars 2025 Retour au numéro
Article précédent
- Skull base meningiomas: A bibliometric analysis and comprehensive overview of clinical reports
- Hrvoje Barić, Sara Komljenović, Sergio Garcia Garcia, Mika Niemelä
- Is endoscopic optic nerve decompression useful in cases of optic neuropathy secondary to pachymeningitis?
- Jonathan G.F. Smith, Caroline P. Smith, Philip Weir, Brendan C. Hanna
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?